Christopher Chapple led the peer-review process as the Associate Editor responsible for the paper.
Clinical value of a patient-reported goal-attainment measure: the global development of self-assessment goal achievement (SAGA) questionnaire for patients with lower urinary tract symptoms
Article first published online: 19 FEB 2013
© 2013 Wiley Periodicals, Inc.
Neurourology and Urodynamics
Volume 33, Issue 1, pages 90–94, January 2014
How to Cite
Khullar, V., Espuna-Pons, M., Marschall-Kehrel, D., Fianu-Jonasson, A., Kelleher, C. J., Brubaker, L., Beach, J., Piault, E. and Trocio, J. (2014), Clinical value of a patient-reported goal-attainment measure: the global development of self-assessment goal achievement (SAGA) questionnaire for patients with lower urinary tract symptoms. Neurourol. Urodyn., 33: 90–94. doi: 10.1002/nau.22377
V.K. is a consultant to Pfizer, Astellas, and Allergan. M.E. is a consultant to Pfizer and Astellas. D.M.K. is a consultant to Pfizer, Ferring, Astellas, Bayer, and Lilly. A.F.J. has nothing to declare. C.K. is a consultant to Pfizer, Astellas, and Allergan. L.B. has nothing to declare. J.B. is a consultant to Pfizer, GlaxoSmithkline, Astra Zeneca, BMS, Regemeron, and Merck. L.P. is an employee of Adelphi Values (formerly Mapi Values) who were paid consultants to Pfizer Inc. J.T. is an employee of Pfizer Inc.
- Issue published online: 11 DEC 2013
- Article first published online: 19 FEB 2013
- Manuscript Accepted: 7 JAN 2013
- Manuscript Received: 23 AUG 2012
- Pfizer Inc
- lower urinary tract;
- overactive urinary bladder;
- signs and symptoms;
- treatment outcome
To discuss the importance of patients' treatment goals and perceived goal attainment to better address expectations in the treatment of lower urinary tract symptoms (LUTS), including overactive bladder (OAB).
The development of the Self-Assessment Goal Achievement (SAGA) questionnaire was driven by measurement principles from the field of qualitative and psychometric research adapted to elicit patients' treatment goals. At baseline, SAGA solicits individualized responses of patient's treatment expectations and goals, and at follow-up SAGA uses a goal-attainment scale (GAS) to document goal achievement.
The SAGA questionnaire provides a basis for the patient and physician to discuss realistic treatment expectations and to measure the alignment between patients' expectations and treatment outcomes in terms of improvement in symptoms and impact on function. Therefore, incorporating the SAGA questionnaire into clinical trials may provide an additional dimension of treatment efficacy by incorporating data on treatment satisfaction from the patient's perspective.
The SAGA questionnaire is a useful tool for patient-centered discussions about the treatment and management of LUTS, including OAB, and assisting physicians in tracking progress and managing patient expectations during therapy. Neurourol. Urodynam. 33:90–94, 2014. Copyright © 2013 Wiley Periodicals, Inc.